In this edition:
Tumour Treating Field therapy in metastatic NSCLC
Neoadjuvant nivolumab by definitive surgery in resectable NSCLC
Nivolumab/ipilimumab/chemotherapy in metastatic NSCLC
KRAS status in atezolizumab treated stage II-IIIA NSCLC
Clinical relevance of early liquid biopsy for suspicious metastatic lung cancer
ctDNA dynamics and survival outcomes in advanced NSCLC
Datopotamab deruxtecan in advanced aNSCLC
Sotorasib + carboplatin-pemetrexed for non-squamous, NSCLC with KRAS G12C
Pembrolizumab, resection and adjuvant pembrolizumab for early-stage NSCLC
Adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA NSCLC
Please login below to download this issue (PDF)